Workshops & Webinars 2024
Our exciting initiative continues!
Our Experts to Experts Program aims to intensify the dialogue between you and our experts through on-site workshops and webinars. This program offers a continuous exchange of knowledge for the entire Zytomed Systems product portfolio. Explore your options.
You can request the program including a series of scientific activities for the upcoming months at workshop@zytomed-systems.de or webinar@zytomed-systems.de.
If you need further information or have any questions, please do not hesitate to contact us.
Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated. For the first time it is recommended to sequence genes involved in homologous recombination repair (HRR), e. g. ATM, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, HDAC2 and PALB2, before initiating a systemic therapy for castration-resistant prostate cancer (mCRPC).